CS
CERE

Credit Suisse’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Credit Suisse’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$4.72M Sell
111,634
-62,864
-36% -$2.64M ﹤0.01% 1329
2023
Q4 		$7.4M Buy
174,498
+112,924
+183% +$3.24M 0.01% 1104
2023
Q3 		$1.34M Sell
61,574
-11,199
-15% -$280K ﹤0.01% 2088
2023
Q2 		$2.31M Buy
72,773
+17,304
+31% +$531K ﹤0.01% 1815
2023
Q1 		$1.35M Buy
55,469
+17
+0% +$499 ﹤0.01% 2121
2022
Q4 		$1.75M Buy
55,452
+5,416
+11% +$153K ﹤0.01% 1962
2022
Q3 		$1.42M Buy
50,036
+1,533
+3% +$45.7K ﹤0.01% 2079
2022
Q2 		$1.28M Buy
48,503
+11,622
+32% +$330K ﹤0.01% 2214
2022
Q1 		$1.29M Buy
36,881
+4,920
+15% +$144K ﹤0.01% 2369
2021
Q4 		$1.04M Buy
31,961
+4,464
+16% +$158K ﹤0.01% 3288
2021
Q3 		$811K Buy
27,497
+12,235
+80% +$343K ﹤0.01% 3493
2021
Q2 		$391K Buy
15,262
+2,315
+18% +$33.1K ﹤0.01% 3986
2021
Q1 		$178K Buy
+12,947
New +$189K ﹤0.01% 4146

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Credit Suisse's CERE Position: Q1 2024 in Review

Credit Suisse reduced its Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) stake by 36% in Q1 2024, selling an estimated $2.64M and leaving 111,634 shares worth $4.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

Credit Suisse first reported a position in CERE in Q1 2021 and has held it in 13 quarters since. The position peaked at $7.4M in Q4 2023. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • Credit Suisse held 111,634 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $4.72M as of Q1 2024.
  • Credit Suisse sold 62,864 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $2.64M.
  • Cerevel Therapeutics Holdings, Inc. Common Stock made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1329 holding.
  • Credit Suisse first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and has held it in 13 quarters since.
  • Credit Suisse's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $7.4M in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.